Saturday, June 21, 2025
VISIT ROYALMOK
Agarwood Times
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
Agarwood Times
No Result
View All Result

Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy

March 8, 2025
in Health
Reading Time: 3 mins read
0 0
A A
0
Home Health
Share on FacebookShare on Twitter


A despair drug candidate that’s a key a part of Johnson & Johnson’s neuroscience technique has failed a Part 3 scientific trial, the most recent dose of disappointing information for an rising class of medicines addressing a novel goal hoped to beat limitations of at the moment accessible antidepressants.

J&J is discontinuing the Part 3 check of its drug, aticaprant, in main depressive dysfunction “as a consequence of inadequate efficacy within the goal affected person inhabitants,” the corporate stated after Thursday’s market shut. The pharmaceutical large stated this drug was secure and well-tolerated by sufferers, and no new security indicators have been recognized. No different particulars in regards to the trial outcomes have been disclosed.

The open-label scientific trial’s focused enrollment was 840 adults ages 18 to 74. Individuals obtained aticaprant as soon as day by day as an adjunct to despair medicine they have been already taking. Efficacy objectives for the 54-week examine embrace measuring the proportion of sufferers with suicidal ideas or behaviors in addition to the change in rating over time in line with a scale used to evaluate despair signs.

The trial additionally measured for weight acquire and sexual dysfunction, opposed results which might be widespread with at the moment accessible despair medicines and lead many sufferers to cease taking them. Aticaprant was hoped to keep away from or not less than scale back these unwanted side effects. Higher efficacy and improved security and tolerability can be key benefits over the present slate of antidepressants. Analysts had projected aticaprant would grow to be a blockbuster product.

J&J stated evaluation of the failed examine is underway and extra particulars will likely be introduced at a future medical assembly. However despite the fact that this Part 3 trial is ending, J&J isn’t giving up on aticaprant. Primarily based on the potential of the drug’s mechanism, the corporate stated it’s going to discover future improvement alternatives in different areas of excessive unmet want.

Aticaprant is a small molecule designed to focus on and block kappa opioid receptors, an method supposed to modulate pathways that regulate temper and conduct. It’s the identical goal hit by Neumora Therapeutics’ lead drug candidate, navacaprant. In January, Neumora reported this day by day capsule didn’t beat a placebo on the primary efficacy aim of a Part 3 scientific trial.

Earlier this week, Neumora stated it’s going to finish the failed Part 3 examine, one in all three late-stage assessments for navacaprant. However the firm additionally stated it’s going to apply learnings from the failed check to the 2 different Part 3 research, which have been paused for now. Adjustments embrace optimizing web site choice and enhancing medical monitoring to make sure acceptable sufferers are enrolled. Neumora plans to renew the 2 research later this month; preliminary knowledge are anticipated in 2026. Neumora additionally stopped a Part 2 check of navacaprant in bipolar despair so as to commit its sources to its main depressive dysfunction scientific analysis.

[Paragraph added with analyst comments.] In a be aware despatched to buyers Friday, William Blair analyst Myles Minter acknowledged Neumora’s explanations for the trial failure and the deliberate changes to the 2 different Part 3 assessments. However he added that the back-to-back Part 3 misses for Neumora and J&J towards the kappa opioid receptor diminishes confidence on this goal as a mechanism for treating main depressive dysfunction. The agency has lowered the Neumora examine’s likelihood of success to five% and likewise downgraded the biotech’s shares.

As for J&J, the corporate’s neuroscience portfolio consists of the blockbuster schizophrenia drug Invega and the nasal spray despair drug Spravato. The pharma large is bringing a despair drug prospect into the fold by way of the $14 billion acquisition of Intra-Mobile Therapies introduced in January. Intra-Mobile’s fundamental asset is Caplyta, which has approvals in schizophrenia and bipolar despair. The drug is at the moment beneath FDA evaluate for main depressive dysfunction, a sign that would make the once-daily capsule a blockbuster vendor. J&J expects to finish the Intra-Mobile acquisition later this 12 months.

Picture: Mario Tama, Getty Photos



Source link

Tags: DepressionDiscontinuesDrugdueefficacyJohnsonLackpivotaltrial
Previous Post

AI unlocks genetic keys to better colorectal cancer survival

Next Post

Please participate in the RUC survey of unattended sleep testing codes

Related Posts

Racial, ethnic differences seen in teens’ use of mental health services
Health

Racial, ethnic differences seen in teens’ use of mental health services

June 21, 2025
Study reveals intercellular flow as crucial factor in tissue mechanics
Health

Study reveals intercellular flow as crucial factor in tissue mechanics

June 21, 2025
Dosing questions surround Novo Nordisk next-gen weight loss drug
Health

Dosing questions surround Novo Nordisk next-gen weight loss drug

June 21, 2025
Bluebird Kids Health to Expand By Opening New Pediatric Clinics
Health

Bluebird Kids Health to Expand By Opening New Pediatric Clinics

June 21, 2025
Why acute and chronic pain are so different—and what might make pain last
Health

Why acute and chronic pain are so different—and what might make pain last

June 20, 2025
Transfer RNA-derived small RNAs transform the landscape of liquid biopsy
Health

Transfer RNA-derived small RNAs transform the landscape of liquid biopsy

June 20, 2025
Next Post
Please participate in the RUC survey of unattended sleep testing codes

Please participate in the RUC survey of unattended sleep testing codes

Interim data on flu vaccines estimate overall moderate protection in Europe, China

Interim data on flu vaccines estimate overall moderate protection in Europe, China

US flu ebbs for third straight week, but impact on healthcare remains

US flu ebbs for third straight week, but impact on healthcare remains

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

What You Need to Know About the Health Risks (and Benefits) of Grilled Meat
Diet & Fitness

What You Need to Know About the Health Risks (and Benefits) of Grilled Meat

by admin
June 18, 2025
0

If you happen to’re on the lookout for lean protein, grilling up fish or hen breast is an interesting selection....

Blueberry Oatmeal Breakfast Cookies

Blueberry Oatmeal Breakfast Cookies

June 16, 2025
Ooud Arabia Fragrans – Makhallat

Ooud Arabia Fragrans – Makhallat

June 19, 2025
Autoimmunity: What Happens When Your Cells Run on Empty

Autoimmunity: What Happens When Your Cells Run on Empty

June 19, 2025
Puberty blockers do not cause problems with sexual functioning in transgender adults, study finds

Puberty blockers do not cause problems with sexual functioning in transgender adults, study finds

June 18, 2025
Singaporean doctors develop agentic AI-powered scribe

Singaporean doctors develop agentic AI-powered scribe

June 17, 2025
Facebook Twitter Instagram Youtube RSS
Agarwood Times

Stay informed with the latest news, articles, and insights on agarwood cultivation, history, sustainability, and more. Explore the timeless allure of agarwood and deepen your understanding of this extraordinary natural resource.

CATEGORIES

  • Agarwood
  • Diet & Fitness
  • Diseases
  • Health
  • Meditation
  • Nutrition
  • Sleep Info
  • Uncategorized
No Result
View All Result

SITEMAP

  • About us
  • Advertise With Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
VISIT ROYALMOK

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In